Assays for Measuring C. difficile Toxin Activity and Inhibition in Mammalian Cells by Cox, Mary Ann et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Assays for Measuring C. difficile Toxin Activity and
Inhibition in Mammalian Cells
Mary Ann Cox, Lorraine D. Hernandez, Pulkit Gupta,
Zuo Zhang, Fred Racine and Alex G. Therien
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/68127
Abstract
Clostridium difficile infections (CDIs) are the leading cause of hospital-acquired infectious 
diarrhea. The symptoms of CDI are caused by two exotoxins, TcdA and TcdB, which are 
structurally and functionally highly homologous. Both toxins bind to specific receptors 
on mammalian cells, are internalized through endocytosis, translocate to the cytoplasm, 
and inactivate Rho-type GTPases via covalent glucosylation. This leads to downstream 
events that include morphological changes and disruption of epithelial tight junctions, 
release of pro-inflammatory mediators, and cell death. Assays used to assess the effects 
of toxins on cells have historically relied on evaluation of cell rounding or quantitation 
of ATP levels to estimate cell death—assays which can be qualitative and variable. In this 
chapter, several assays are described that robustly and quantitatively measure early and 
late toxin-dependent events in cells, including (i) toxin binding, (ii) Rac1 glucosylation, 
(iii) changes in cellular morphology (measured as dynamic mass redistribution), (iv) loss 
of epithelial integrity (measured as transepithelial electrical resistance), and (v) cell death 
(measured as total cellular protein using a colorimetric assay). The assays were validated 
using the highly specific monoclonal antitoxin antibodies, actoxumab and bezlotoxumab, 
which neutralize TcdA and TcdB, respectively.
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1. Introduction
Clostridium difficile (C. difficile) is an anaerobic, gram-positive, spore-forming bacterium 
that colonizes the lower intestinal tract of patients whose normal gut microflora has been 
 disrupted by treatment with broad-spectrum antibiotics [1]. The symptoms of C. difficile 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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 infection (CDI)—which include diarrhea and, in severe cases, pseudomembranous colitis, 
colonic rupture, and death [1, 2]—are caused by two exotoxins, toxin A (TcdA) and toxin 
B (TcdB) [3]. Both toxins have similar structural and functional characteristics. After bind-
ing to specific receptors on the surface of gut epithelial cells, they are internalized through 
 endocytosis, translocate to the cytoplasm, and inactivate Rho-type GTPases via covalent 
glucosylation [4–7]. This leads to a variety of downstream events, including morphological 
changes associated with disruption of epithelial tight junctions, release of pro-inflammatory 
mediators (including interleukin-1β, tumor necrosis factor alpha, and interleukin-8), and 
eventually cell death [3, 8]. The damaging effects on the gut epithelium and initiation of a 
host inflammatory response are thought to underlie the clinical manifestation of CDI.
Current treatment for C. difficile infections includes discontinuing the offending  broad- spectrum 
antibiotic and initiating therapy with narrower spectrum agents such as vancomycin, metro-
nidazole, or fidaxomicin [9, 10]. Unfortunately, these treatments do not directly address the 
damaging effects of the toxins on the gut and perpetuate the gut dysbiosis that caused CDI in 
the first place. As a result, up to 25% or more patients successfully cured of an initial episode 
of CDI with these antibiotics suffer a recurrent episode within days to weeks. To address 
this, recent approaches to CDI treatment, including vaccines and monoclonal antibodies, have 
focused on neutralizing the effects of TcdA and TcdB, specifically, rather than the organisms 
itself [11–13]. Foremost among these novel therapies is bezlotoxumab, the anti-TcdB antibody 
recently approved by the Food and Drug Administration for reducing recurrence of CDI in 
patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and 
are at a high risk for CDI recurrence.
The renewed interest in toxin-directed therapies underscores the importance of having robust 
quantitative assays in place to assess the activity of the C. difficile toxins. Historically, studying 
the effects of TcdA and TcdB on mammalian cells has been hampered by time-consuming and 
subjective assays that rely, for example, on visualization of cells to assess cell rounding or on the 
variable quantitation of ATP levels to measure cell death [13]. Thus, there is a scarcity of robust 
quantitative assays that measure the various cellular events associated with the intoxication 
cascade, making it difficult to evaluate new toxin-directed agents. In this chapter, we describe 
multiple quantitative cell-based assays that were newly developed, or adapted and optimized 
from previous reports, and used to interrogate the effect of the C. difficile toxins on epithelial 
cells. The assays are validated using the highly specific and potent antitoxin antibodies, actox-
umab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively [13–15].
2. Materials and methods
2.1. TcdA- and TcdB-binding assay (Western blot)
TcdA (1 μg/ml) or TcdB (0.1 μg/ml) (The Native Antigen Company, Upper Heyford, the UK 
and tgcBIOMICS, Bingen, Germany) was incubated with or without 200 μg/ml actoxumab or 
bezlotoxumab in Vero cell culture medium (Eagle’s minimal essential medium (EMEM) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 U/ml  streptomycin) 
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for 30 min at 37°C; these mixtures were then chilled on ice and added to plates of pre-chilled 
Vero cells (ATCC, Rockville, MD). Plates were incubated for 30 min on ice to allow binding of 
toxins. Following incubation, plates were washed three times with cold phosphate buffered 
saline (PBS) and cells were harvested by scraping. Cell membranes were isolated at 4°C with 
the Mem-PER Plus Membrane Protein Extraction Kit (Thermo Scientific, Grand Island, NY), 
according to the manufacturer’s instructions, and solubilized in a total volume of 100 μL solu-
bilization buffer with HALT protease/phosphatase inhibitors (Thermo Scientific). Following 
addition of Laemmli sample buffer, samples were incubated for 5 min at 95°C and resolved 
by SDS PAGE in 4–12% polyacrylamide gels and transferred to a nitrocellulose membrane. 
The nitrocellulose membrane containing transferred protein was blocked in Odyssey blocking 
buffer (Li-Cor) followed by incubation with actoxumab, bezlotoxumab, or an anti-cadherin 
antibody (Cell Signaling Technology, Beverly, MA) as the primary antibody for 1 h at room 
temperature (RT). After washing, the nitrocellulose membrane was incubated with a goat anti-
human IgG antibody coupled to IRDye® 800CW (Li-Cor) for 30 min at RT. After additional 
washing, bands were visualized using the Odyssey imaging system (Li-Cor).
2.2. TcdA-binding assay (flow cytometry)
TcdA, from ribotype 087 (The Native Antigen Company, Upper Heyford, the UK), was 
 fluorescently labeled using the Lightning Link Atto488 Antibody Labeling kit (Novus 
Biosciences, Littleton, CO) as directed by the manufacturer. About 50 μg of lyophilized 
TcdA was reconstituted for a minimum of 30 min in sterile ddH2O at RT before adding the 
LL-modifier buffer. The toxin/LL-modifier buffer solution was transferred to a vial containing 
the lyophilized Lightning Link mix. The mixture was pipetted up and down and incubated 
at RT in the dark. After 5 h, LL-quencher buffer was added and incubated at RT in the dark 
for 30 min and then stored at 4°C until use the following day. Several concentrations of TcdA-
Atto488 were incubated with or without 200 μg/ml actoxumab at RT for 60 min,  protected 
from light. Samples were then chilled on ice. Adherent HT29 cells (ATCC, Rockville, MD) 
were resuspended in the cell medium (McCoy’s 5A Modified medium supplemented with 
10% FBS, 2 mM glutamine, 0.75% sodium bicarbonate, 100 U/ml penicillin, and 100 U/ml 
streptomycin), following treatment with Accutase (Innovative Cell Technologies), washed 
once with cold Dulbecco’s phosphate-buffered saline with calcium and magnesium (DPBS++) 
containing 1% bovine serum albumin (BSA), and then chilled on ice. 100 μL of each toxin/
antibody sample was added to separate vials containing 3 × 105 cells. After mixing, samples 
were incubated on ice in the dark. After 30 min, 1 ml of ice cold DPBS++/1% BSA was added 
to each sample. To remove unbound toxin, cell suspensions were washed twice with ice cold 
DPBS++/1% BSA by centrifuging for 5 min at 4°C at 200 × g and removing the supernatant. 
Washed cells were resuspended in 500 μl cold DPBS++/1% BSA and analyzed by flow cytom-
etry using an LSRII instrument (BD Biosciences) with excitation and emission wavelengths of 
488 and 530 nm, respectively. 10,000 events were measured for each sample.
2.3. Rac1 glucosylation assay
Vero cells were seeded at a cell density of 5 × 103 cells/well in a 384-well collagen-coated plate 
and grown overnight at 37°C in 5% CO
2
. TcdA and TcdB (The Native Antigen Company, 
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Upper Heyford, the UK and tgcBIOMICS, Bingen, Germany) were serially diluted in Vero 
cell culture medium, and 50 μl was added to each well. For assays determining neutralization 
effects of actoxumab and bezlotoxumab, TcdA and TcdB were pre-incubated at 90% effective 
concentrations (EC
90
) with actoxumab and bezlotoxumab, respectively (various concentra-
tions), for 1 h at RT in Vero cell culture medium, prior to addition of cells as above. Following 
incubation at 37°C in 5% CO
2
 for 3 h, medium containing toxin alone or toxin+antibody 
was removed by aspiration. Cells were immediately fixed with 50 μl/well fixing solution 
(4%  paraformaldehyde in modified Dulbecco’s phosphate-buffered saline (DPBS/modified)) 
for 1 h at RT. Following fixation, cells were washed four times for 5 min with 50 μl/well 
permeabilization solution (0.1% Triton-X-100 in DPBS/modified) at RT with gentle shaking. 
Cells were then blocked with 50 μl/well Odyssey blocking buffer (Li-Cor) overnight at 4°C. 
After removing blocking buffer, cells were incubated with 25 μl/well mouse anti-Rac1 (BD 
Biosciences #610651, recognizing non-glucosylated Rac1), or anti-Rac1 clone 23A8 (Millipore 
#05-389, recognizing total Rac1), diluted at 1:75 and 1:200, respectively, in Odyssey blocking 
buffer and incubated for 2 h at RT with gentle shaking. Cells were washed four times for 
5 min with 50 μl/well wash solution (0.1% tween 20 in DPBS/modified) at RT with gentle 
 shaking. Cells were then incubated with 25 μl/well secondary antibodies (IRDye 800 CW 
goat anti-mouse and CellTag 700 stain, diluted at 1:800 and 1:1000, respectively, in Odyssey 
 blocking buffer) at RT for 1 h with gentle shaking protected from light. Cells were again 
washed four times for 5 min with 50 μl/well wash solution at room temperature with gentle 
shaking. After the final wash, any remaining solution was removed from the wells, and the 
plates were scanned on the Li-Cor Odyssey classic (Li-Cor) with detection in both 700 and 
800 nm  channels (A700 and A800). Cell number normalization/well was calculated using the 
ratio of A800/A700, and remaining percent of non-glucosylated Rac1 was determined using 
the ratio of normalized A800 of treated cells/normalized A800 of untreated cells multiplied 
by 100. Analysis was performed with GraphPad Prism (version 6.04) using the 4-parameter 
nonlinear regression formula.
2.4. Dynamic mass redistribution (Epic) assay
Vero cells were seeded at a cell density of 5 × 103 cells/well in a 384-well fibronectin-coated 
Epic plate (Corning #5042) and grown overnight at 37°C in 5% CO
2
. On the day of assay, 
medium was aspirated and replaced with 40 μl/well assay buffer (HBSS in 20 mM HEPES) 
and equilibrated at RT for 1 h. TcdA and TcdB (The Native Antigen Company, Upper 
Heyford, UK and tgcBIOMICS, Bingen, Germany) were serially diluted in assay buffer and 
equilibrated at RT for approximately 10 min. For assays determining neutralization effects of 
 actoxumab and  bezlotoxumab, TcdA and TcdB were pre-incubated at EC
90
 concentrations for 
1 h at RT with actoxumab and bezlotoxumab, respectively (various concentrations). Following 
 pre- incubations, 10 μl/well of the toxins alone or toxin/antibody solutions were added to Vero 
cells using a Matrix Platemate (Thermo Scientific) and gently mixed. The plate was read every 
12 s for 200 min using the Epic BT-157900 (Corning). As a baseline, wells containing assay 
 buffer alone were used. The dynamic mass redistribution (DMR) values were recorded at 
180 min at which point the signal had plateaued (not shown). The recorded DMR values 
( corrected for assay buffer alone) were collected with EpicAnalyzer software and analyzed 
with GraphPad Prism (version 6.04) using the four-parameter nonlinear regression formula.
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2.5. Transepithelial electrical resistance (TER) assay
To initiate the 2-dimensional culture system, 0.5–1 × 105 Caco-2 cells (ATCC, Rockville, MD) 
were seeded into each well of the 24-well insert plates (Falcon #351181 HTS Multiwell Insert 
System—1.0 um pore size/PET membrane), with 250 μl Caco-2 cell culture medium (EMEM 
supplemented with 10% FBS, 1× non-essential amino acid, 0.075% sodium  bicarbonate, 100 U/ml 
penicillin, and 100 U/ml streptomycin) in the apical chamber and 800 μl in the basolateral 
chamber. Caco-2 cells were cultured for at least 14 days at 37°C with 5% CO
2
 to ensure full 
differentiation and confluency, which were confirmed by plateauing of the TER reading at 
≥ 600 Ω cm2. TER was measured using the Epithelial Volt-Ohm Meter Millicell ERS-2 (EMD 
Millipore, Billerica, MA, USA). To assess the effect of toxins on the cell monolayer, TcdA and 
TcdB (The Native Antigen Company, Upper Heyford, UK and tgcBIOMICS, Bingen, Germany) 
were added to the apical chamber. To evaluate the ability of the antibodies to neutralize toxin 
effects, actoxumab or bezlotoxumab was added to the apical chamber immediately before 
addition of TcdA or TcdB to the apical chamber. For neutralization studies, 10 ng/ml TcdA 
was combined with various concentrations (from 0 to 50 μg/ml) of actoxumab, and 100 ng/ml 
TcdB was combined with various concentrations (from 0 to 100 μg/ml) of bezlotoxumab. TER 
measurements were obtained immediately before and, at 6, 24, and 48 h, after addition of tox-
ins/antibodies to the apical chamber. TER values were normalized to values obtained in the 
absence of toxin at each time point to account for minor time-dependent variability.
2.6. Sulforhodamine B assay
To study the effects of C. difficile toxins on cytotoxicity and the ability of actoxumab and 
bezlotoxumab to neutralize those effects, the sulforhodamine B (SRB) assay was employed to 
measure total cellular protein as a surrogate of cell number [16]. Vero or T-84 (T-84 growth 
medium—DMEM/F-12K supplemented with 5% FBS, 2 mM l-glutamine, 100 U/ml  penicillin, 
100 U/ml streptomycin) cells were seeded into 96-well plates at 2000 and 3000 cells/well, 
respectively, and incubated overnight at 37°C with 5% CO
2
. Varying concentrations of puri-
fied TcdA and TcdB (tgcBIOMICS, Bingen, Germany) were diluted in the appropriate growth 
media, incubated at 37°C for 2 h, and added to cells. Following a 24-h incubation at 37°C 
with 5% CO
2
, the medium was aspirated and plates were washed twice with PBS. About 
200 μl per well of complete medium was added, and plates were incubated for an additional 
48 (Vero cells) or 72 h (T-84 cells). After incubation, the medium was removed, and cells 
were fixed with 100 μl/well of 10% cold trichloroacetic acid (TCA) for 1 h at 4°C. The TCA 
was then removed and plates were washed four times with distilled water. After washing, 
100 μl/well of 100 μg/ml SRB in 10% acetic acid was added, and plates were incubated for 
15 min at room temperature (RT). The plates were then washed four times with 10% acetic 
acid and air-dried. Addition of 150 μl/well of 10 mM tris was followed by a 10-min incuba-
tion at RT with shaking. Absorbance was then measured at 570 nm with a SpectraMax plate 
reader (Molecular Biosystems). Treated and untreated cells were compared, and 90% lethal 
concentrations (LC
90
 , that is, concentrations of TcdA or TcdB required to cause a 90% reduc-
tion in cell number) were calculated. Antibody-mediated toxin neutralization was measured 
by  incubating serially diluted actoxumab or bezlotoxumab (at concentrations ranging from 
1 ng/ml to 192 μg/ml) with purified TcdA or TcdB at LC
90
 for 2 h at 37°C. The toxin/antibody 
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mixtures were then added to Vero or T-84 cells as described above and incubated for 24 h at 
37°C with 5% CO
2
. The cells were then washed twice with PBS and treated and analyzed as 
described above.
To assess the cytotoxicity of C. difficile toxins derived from bacterial culture superna-
tants, strain VPI 10463 (ribotype 087) (ATCC) was grown in chopped meat medium 
(Anaerobe Systems) under anaerobic conditions at 37°C for 72–96 h, and culture superna-
tants were  collected,  filtered twice through a 0.22 μm filter, and stored at 4°C. For TcdB 
 immunodepletion, cell  culture supernatants were combined and mixed with bezlotoxumab 
and protein A-agarose beads for 4–6 h at 4°C. After incubation, the beads were removed 
by  centrifugation. Supernatants were then collected, filtered (0.22 μm), and stored at 4°C. 
Cytotoxicity and antibody- mediated  neutralization of the untreated (for determinations on 
TcdB) or immunodepleted (for  determinations on TcdA) supernatants were measured as 
described above.
3. Results
3.1. Overview of mammalian cell intoxication by TcdA and TcdB
TcdA and TcdB are large, monomeric proteins (300 and 270 kDa, respectively) with sim-
ilar structures and functions (Figure 1) [17, 18]. The functional domains of the toxins are 
arranged according to the ABCD model [17]: the N-terminal A domain contains the glu-
cosyltransferase enzymatic activity, the B domain is a putative receptor-binding domain 
composed of a series of long and short repeats known as combined repetitive oligopeptides 
(CROPs), the cysteine protease (C) domain is responsible for autocatalytic processing, and 
the D domain is involved in pore formation and toxin translocation. Both toxins bind to 
receptors on the surface of the epithelial cells that line the wall of the lower intestine (and 
possibly other cell types). Once bound, they are internalized via receptor-mediated endo-
cytosis [19]. Acidification of the endosome promotes a conformational change that enables 
translocation of the N-terminal glucosyltransferase domain of the toxin into the cytoplasm. 
Cellular inositol  hexakisphosphate (InsP6) allows cleavage of the toxin by the cysteine pro-
tease domain, releasing the glucosyltransferase domain into the cytoplasm where it inacti-
vates Rho-type GTPases through covalent glucosylation (from UDP-glucose) [20]. This in 
turn causes changes in epithelial cell morphology due to actin depolymerization, loss of tight 
junction integrity, and eventually, cell death (Figure 1) [21]. The assays described in this 
chapter measure many of the various steps, described above, involved in the intoxication 
cascade (steps 1–5, as denoted in Figure 1).
3.2. Cell surface binding of TcdA and TcdB (step 1 in Figure 1)
Binding of toxins to the cell surface of target cells is the first step in TcdA and TcdB cell 
entry, leading to the downstream effects of the toxins. We assessed cell surface binding of 
TcdA and TcdB by Western blotting of cell membranes isolated from Vero cells incubated 
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with TcdA or TcdB at 4°C. As shown in Figure 2, membrane fractions isolated from cells 
incubated with TcdA (see Figure 2A, top panel) or TcdB (Figure 2B, top panel) contain 
toxins, indicating cell surface binding of the toxins. Actoxumab and bezlotoxumab bind to 
and neutralize purified TcdA and TcdB, respectively, from a variety of C. difficile strains [15]. 
Pre-incubation of TcdA with actoxumab but not bezlotoxumab efficiently blocked binding 
of TcdA to cells (Figure 2A), while pre-incubation of TcdB with bezlotoxumab but not actox-
umab efficiently blocked binding of TcdB to cells (Figure 2B), confirming the specificity of 
toxins binding to cells.
Figure 1. Clostridium difficile toxin structure and mechanism of action. (A) Domain organization of TcdA. (B) Domain 
organization of TcdB. (C) Mechanism of intoxication of mammalian cells by TcdA and TcdB. Toxins A and B bind to 
receptors on the surface of target cells (1) and are endocytosed. Endosomal toxins are acidified causing exposure of 
hydrophobic regions of the protein that allow their insertion into the membrane, forming pore(s). The N-terminal 
catalytic domain is then translocated from the endosomal compartment into the cytoplasm, where the glucosyltransferase 
domain is released by inositol hexakisphosphate (InsP6)-dependent auto-cleavage. The toxins then glucosylate Rho-type 
GTPases (2) from UDP-glucose, causing actin depolymerization, changes in cell morphology (3), disruption of tight 
junctions (4), and cell death (5). Cellular events numbered 1–5 correspond to the steps assessed by the various assays 
described in this chapter. Figure adapted from Jank and Aktories [17].
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Binding of TcdA to cells and the prevention, thereof, by actoxumab were also assessed by 
flow cytometry (Figure 3). Incubation of HT29 cells with increasing levels of fluorescently 
labeled TcdA (TcdA-Atto488) led to an elevated mean fluorescence intensity (MFI), indicating 
binding of TcdA to the cell surface in a concentration-dependent manner. In the presence of 
actoxumab, however, the MFI for each toxin concentration was reduced to background levels 
showing that actoxumab blocked binding of TcdA to the cell surface. No significant changes 
in MFI were measured in the presence of bezlotoxumab, indicating that the effect of actox-
umab is specific (data not shown).
3.3. Glucosylation of Rac1 by TcdA and TcdB (step 2 in Figure 1)
Inactivation of Rho-type GTPases is a key step in the intoxication of host cells, leading to 
the downstream cytopathic and cytotoxic effects of the C. difficile toxins. Historically, the glu-
cosylation of Rho GTPases was assessed by polyacrylamide gel-based assays that use either 
radioactively labeled glucose or antibodies to detect the glucosylated and non-glucosylated 
protein on a gel [22]. These assays are laborious, low throughput, qualitative, and do not 
detect glucosylation directly in the cell. A novel assay was therefore developed to measure 
Figure 2. Cell surface binding of TcdA and TcdB as measured by Western blot. Western blots of cell membranes isolated 
from Vero cells following incubation with (A) TcdA or (B) TcdB, in the presence of vehicle, actoxumab, or bezlotoxumab 
(200 μg/ml), as indicated. The top blots in each panel show TcdA and TcdB, while the bottom blots show cadherin, used 
as a loading control.
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TcdA- and TcdB-mediated Rac1 glucosylation in a high throughput and quantitative 384-well 
in-cell Western assay, using antibodies that detect non-glucosylated and total Rac1. A dose-
dependent decrease in non-glucosylated Rac1 was observed in the presence of TcdA and TcdB 
from various ribotypes (027, 078, and the control 087 (strain VPI 10463)) (Figure 4A and B), 
while total Rac1 was minimally affected (not shown). Vero cells were found to be more sensi-
tive to TcdB than TcdA, consistent with previous observation by Torres et al. [23]. In addition, 
differences in sensitivity of Vero cells to toxins of the different C. difficile ribotypes were noted. 
For instance, Vero cells were found to be more sensitive to TcdA of ribotype 087 (VPI 10463) 
than of ribotypes 027 and 078, while TcdB showed the opposite effect, with cells being more 
sensitive to TcdB of ribotypes 027 and 078 compared to ribotype 087.
Actoxumab and bezlotoxumab neutralized the effects of TcdA and TcdB (at EC
90 
concentra-
tions), respectively (Figure 4C and D). Notably, the potency of actoxumab and  bezlotoxumab 
on their respective toxins was lower for toxins of ribotype 027 and 078 compared to  ribotype 
087. This is consistent with the lower affinities of the antibodies against toxins of these 
 ribotypes, as previously described by Hernandez et al. [15].
3.4. Changes in cell morphology induced by TcdA and TcdB (step 3 in Figure 1)
The cytopathic effects of TcdA and TcdB on gut epithelium are visualized as profound morpho-
logical changes, typically cell rounding, due to the glucosylation and inactivation of Rho-type 
GTPases and subsequent disruption of actin polymerization. Historically, these cytopathic 
Figure 3. Cell surface binding of TcdA as measured by flow cytometry. A representative experiment showing flow 
cytometry analysis of HT29 cells pre-incubated with a titration of TcdA-Atto488 in the presence or absence of actoxumab. 
Following incubation, mean fluorescence intensity (MFI) was measured with excitation and emission wavelengths of 488 
and 530 nm, respectively.
Assays for Measuring C. difficile Toxin Activity and Inhibition in Mammalian Cells
http://dx.doi.org/10.5772/68127
119
effects have been assessed qualitatively through visual determination of cell rounding [23]. 
Improved phenotypic assays used to investigate changes in cell morphology involve the quan-
tification of length-to-width ratios of fluorescently labeled cells [23, 24]. This latter technique 
is quantitative and has an improved throughput, although it requires consistent staining and 
substantial data analysis. To better understand and quantify toxin-induced morphological 
changes in unlabeled cells, an assay was developed to examine dynamic mass distribution 
(DMR) in Vero cells using the Epic instrument. In this assay, plates containing optical sen-
sors are used to capture translocation of cellular mass of unlabeled cells in response to ligand 
binding, allowing changes in cell shape to be quantified. The concentration-dependent effects 
of TcdA and TcdB on mass redistribution were determined at 180 min (at which time the 
effects have plateaued, not shown) (Figure 5A). As with the Rac1 glucosylation assay, Vero 
cells are much more sensitive to TcdB than TcdA in the DMR assay. The neutralizing effects of 
actoxumab and bezlotoxumab on toxin-induced morphological changes were assessed at EC
90
 
concentrations of TcdA and TcdB, respectively. Actoxumab and bezlotoxumab fully neutral-
ized the effects of TcdA and TcdB, respectively, on DMR (Figure 5B).
Figure 4. TcdA- and TcdB-mediated Rac1 glucosylation and neutralization thereof by actoxumab and bezlotoxumab. 
Effect of TcdA (A) and TcdB (B) of ribotypes 027, 078, and 087 on glucosylation of Rac1. Neutralization of TcdA-mediated 
Rac1 glucosylation by actoxumab (C) and of TcdB-mediated Rac1 glucosylation by bezlotoxumab (D).
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3.5. Toxin-induced disruption of epithelial tight junctions (step 4 in Figure 1)
To gain an understanding of the effect of C. difficile toxins on the integrity of the gut wall 
epithelium, a two-dimensional cell culture system was utilized wherein a single monolayer 
of colonic epithelial cells (Caco-2) is grown on a permeable membrane, separating distinct 
apical and basolateral compartments [25–28]. The system simulates the polarized nature of 
the intact intestinal mucosal epithelium, which separates the gut lumen (apical side) from the 
 subepithelial/systemic space (basolateral side). The integrity of the epithelial layer is  monitored 
by measuring the transepithelial electrical resistance (TER), with a decrease in TER suggesting 
that the integrity of the epithelial monolayer has been compromised [26]. In this system, TcdA 
and TcdB added to the apical side of the cell monolayer (mimicking the presence of toxin on 
the lumenal side of the gut) caused significant time- and concentration-dependent decreases 
in TER (Figure 6A and B). Neutralization of the toxin-induced effects by actoxumab and bezlo-
toxumab was assessed at EC
90
 concentrations of TcdA and TcdB,  respectively. Both antibodies 
dose-dependently neutralized the effects of their respective  toxins (Figure 6C and D).
3.6. Toxin-induced cytotoxicity (step 5 in Figure 1)
The traditional way of assessing the cytoxic effects of C. difficile on host cells involves measuring 
cellular ATP levels of intoxicated cells. This method is plagued with low signal to noise ratios 
and variability due to substantial ATP levels remaining in cells that are not yet dead and still 
undergoing morphological changes due to intoxication [13]. Additionally, normal metabolism-
related fluctuations in ATP levels that are unrelated to cell viability can further affect the assay 
readout. We developed a more robust colorimetric assay that measures  cellular protein content 
as a surrogate of cell growth and survival [14]. The sulforhodamine B (SRB) assay was used 
to determine the cytotoxic effects of purified C. difficile toxins of the reference strain VPI 10463 
(ribotype 087) and from strains of ribotypes from the so-called hyper-virulent  ribotypes 027 
and 078. All toxins tested caused a robust concentration-dependent decrease in cell  viability 
Figure 5. Effects of TcdA and TcdB on dynamic mass redistribution and neutralization by actoxumab and bezlotoxumab. 
(A) Concentration-dependent effects of TcdA and TcdB on DMR. (B) Neutralizing effects of actoxumab and bezlotoxumab 
on toxin-induced effects on DMR.
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(Figure 7A and B). As with other assays described herein and as previously observed by Torres 
et al. [23], Vero cells are significantly more sensitive to TcdB than to TcdA. The ability of actox-
umab and bezlotoxumab to neutralize TcdA and TcdB, respectively, was assessed at toxin con-
centrations that are associated with a 90% decrease in cell viability (LC
90
). Both antibodies fully 
neutralized the effects of their respective toxins from all ribotypes tested (Figure 7C and D). 
However, the neutralization potencies of both antibodies for toxins of ribotypes 027 and 078 
were significantly lower than toxins of ribotype 087, similar to data obtained in the Rac1 glu-
cosylation assay above (Section 2.3) and consistent with previous data in the SRB assay [15].
The robust nature of the SRB assay also allows for the study of the cytotoxic effects of unpu-
rified C. difficile toxins directly from culture supernatants for clinical strains for which puri-
fied toxins are not available. For these studies, Vero cells were treated with serially diluted 
culture supernatants of the reference strain VPI 10463, containing both toxins (not shown), in 
the absence or presence of actoxumab, bezlotoxumab, or the combination of both antibodies. 
In the absence of antibodies, there was a concentration-dependent decrease in cell viability, 
presumably due to the presence of toxin in the supernatant. Addition of actoxumab had no 
effect on the cytotoxicity of supernatant, while addition of 10 μg/ml bezlotoxumab either 
Figure 6. Effects of TcdA and TcdB on integrity of Caco-2 cell monolayers and neutralization by actoxumab and 
bezlotoxumab. Time- and concentration-dependent effects on TER of TcdA (A) or TcdB (B) added to the apical side of 
Caco-2 monolayers. Time- and dose-dependent neutralization of TcdA by actoxumab (C) and of TcdB by bezlotoxumab 
(D), added to the apical side.
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by itself or in combination with 10 μg/ml actoxumab significantly shifted the concentration-
response curve to the right, indicating that most of the cytotoxic activity in the supernatant is 
due to TcdB (Figure 8A). This is not surprising as Vero cells are more sensitive to TcdB than to 
TcdA. To assess the cytotoxic activity associated with TcdA, TcdB was first removed from the 
supernatant using an immunodepletion approach (see Section 2). In this case, 10 μg/ml actox-
umab, alone or in combination with 10 μg/ml bezlotoxumab, shifted the response curve to the 
right, whereas bezlotoxumab showed minimal effect, confirming that the cytotoxic activity 
in immunodepleted supernatants is associated mainly with TcdA (Figure 8B). To confirm 
this finding, full concentration-response curves of actoxumab and bezlotoxumab were gener-
ated against dilutions of intact or immunodepleted supernatants associated with ~90% reduc-
tion in cell viability (EC
90
); actoxumab neutralized the cytotoxic activity of immunodepleted 
supernatants, whereas bezlotoxumab neutralized the cytotoxic activity of intact supernatants, 
and no cross-neutralization was observed (Figure 8C and D). This approach has been used 
successfully to assess the activities of actoxumab and bezlotoxumab on TcdA and TcdB of 
dozens of clinical isolates of C. difficile, covering 18 distinct ribotypes (seven toxinotypes) [15].
Figure 7. Purified TcdA- and TcdB-mediated effects on cell viability and neutralization by actoxumab and bezlotoxumab. 
Reduction in Vero cell viability induced by TcdA (A) and TcdB (B) using purified toxins from ribotypes 087, 027, and 078. 
Neutralization of TcdA by actoxumab (C) and of TcdB by bezlotoxumab (D). Figure reproduced from Hernandez et al. 
[15] (Copyright © American Society for Microbiology [Antimicrob Agents Chemother. 59, 2015, 1052–1060. DOI:10.1128/
AAC.04433-14]).
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4. Conclusions
In this chapter, we have described novel cell-based assays for analyzing multiple distinct 
steps in the intoxication cascade associated with TcdA and TcdB. Unlike historical assays that 
measure toxin effects qualitatively, such as the visual assessment of cell rounding, or are vari-
able and often unreliable, such as quantitation of ATP levels to estimate cell death, the assays 
presented here can quantitatively and robustly assess the effects of toxins in mammalian cells. 
We show how the initial event of toxin binding to host cells can be assessed using cell sur-
face binding assays with labeled or unlabeled toxins in flow cytometry and Western blot for-
mats, respectively. The more proximal events that follow internalization of the toxins, namely 
Rac1 glucosylation and cell rounding, can be studied with novel quantitative assays by in-cell 
Western and dynamic mass redistribution assays, respectively. Finally, we show how the TER 
and SRB assays can be utilized to assess the final stages of intoxication, tight junction disrup-
tion, and cell death, respectively. We also show how the SRB assay can be used to accurately 
measure the activities of TcdA and TcdB from unpurified toxins in culture supernatants of 
Figure 8. Unpurified TcdA- and TcdB-mediated effects on Vero cell viability and neutralization by actoxumab and 
bezlotoxumab. Cytotoxic effects of serially diluted intact (A) or immunodepleted (B) supernatants in the presence or 
absence of actoxumab, bezlotoxumab, or a combination of the two antibodies. Neutralization of cytotoxic activity by 
bezlotoxumab, but not actoxumab, in intact supernatant at EC
90
 dilution (C) and by actoxumab but not bezlotoxumab in 
immunodepleted supernatant at EC
90
 dilution (D).
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C. difficile strains for which purified toxins are not available. The assays described were vali-
dated with the antitoxin antibodies actoxumab (anti-TcdA) and bezlotoxumab (anti-TcdB) to 
demonstrate their utility in evaluating pharmacological blockade of toxins. These assays may 
be useful in future studies aimed at better understanding of C. difficile toxin function, as well 
as in characterizing toxin inhibitors as tools or as potential therapeutics.
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